share_log

Noble Capital Markets Reiterates Outperform on Tonix Pharmaceuticals, Maintains $70 Price Target

Benzinga ·  Mar 20 16:17

Noble Capital Markets analyst Robert LeBoyer reiterates Tonix Pharmaceuticals (NASDAQ:TNXP) with a Outperform and maintains $70 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 2448

Recommended

Write a comment